Clinical Trial for Patients with Relapsed or Refractory DLBCL

A Phase I/II study of combination epigenetic therapy with azacitidine and vorinostat in patients with relapsed and refractory DLBCL

Update: this study is closed to enrollment. 

Researchers have begun to understand how reversible changes in expression of genes contribute to the development of cancer and allow cancer cells to become resistant to the effects of chemotherapy. These reversible changes are termed “epigenetics” since they do not involve mutations in genes themselves.

In this trial we are studying a combination of 2 drugs that may work by reversing epigenetic changes in patients with diffuse large B-cell lymphoma (DLBCL) that has not responded well to chemotherapy.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible. View all posts by lymphomaprogram